New vaccine combo takes on rare belly cancer

NCT ID NCT07341360

Recruiting now Disease control Sponsor: Oslo University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a cancer vaccine (Pseudovax) combined with an immune booster and an immunotherapy drug in 10 people with pseudomyxoma peritonei, a rare abdominal cancer that has come back or cannot be removed. The goal is to see if the treatment is safe and can reactivate the immune system to fight the cancer. Participants must have a specific gene mutation (GNAS) and have no other good treatment options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pseudovax (cancer vaccine), molgramostim (immune booster), and tislelizumab (immunotherapy)
What this could lead to: If it works, this could point toward a new treatment option for people with a rare abdominal cancer that has few alternatives.
What could go wrong: This is a very early, small trial with only 10 participants, so results may not apply widely. The treatment may cause side effects or fail to control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSEUDOMYXOMA PERITONEI are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pseudomyxoma peritonei

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSEUDOMYXOMA PERITONEI

Contacts and locations

Locations

Oslo University Hospital HF, Radium
RECRUITING

Oslo, Oslo, 0379, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.